If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
REYVOW® (lasmiditan): Use With Oral Calcitonin Gene-Related Peptide Receptor Antagonists
Reyvow (lasmiditan) inhibits P-gp and BCRP in vitro. The oral CGRP antagonists, ubrogepant and rimegepant, are both P-gp and BCRP substrates. Concomitant use of lasmiditan and drugs that are P-gp or BCRP substrates should be avoided.
The use of lasmiditan with oral CGRP antagonists has not been studied, and the safety and efficacy of their concomitant use is unknown.
Potential for Drug-Drug Interactions
Concomitant use of lasmiditan and drugs that are P-gp or BCRP substrates should be avoided.1
Enclosed Prescribing Information
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Ubrelvy [package insert]. Madison, NJ: Allergan; 2019.
4Nurtec [package insert]. New Haven, CT: Biohaven; 2021.
BCRP = breast cancer resistance protein
CGRP = calcitonin gene-related peptide
P-gp = P-glycoprotein
Date of Last Review: April 06, 2020